Detail akcie Alnylam Pharm online

Business Summary: Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Alnylam Pharmaceuticals, Inc. revenues increased 23% to $2.25B. Net loss decreased 37% to $278.2M. Revenues reflect AMVUTTRA segment increase of 74% to $970.5M, Regeneron Pharmaceuticals segment increase from $100.5M to $302.8M, United States segment increase of 35% to $933.5M, Europe segment increase of 29% to $516.3M. Lower net loss reflects Interest income increase of 28% to $122M (income).